Evaxion Biotech to Study Lead Candidate EVX-01 With Merck's Keytruda
October 25 2021 - 6:28AM
Dow Jones News
By Colin Kellaher
Evaxion Biotech A/S on Monday said it plans a Phase 2b study of
EVX-01, its lead product candidate, in combination with Merck &
Co.'s blockbuster cancer drug Keytruda in patients with the skin
cancer melanoma.
The Copenhagen biotechnology company said it will be responsible
for conducting the study, which it expects to launch by the end of
the year, while Merck will supply all of the necessary Keytruda and
will continue to collaborate as the study data mature.
Evaxion said the planned multicenter trial will enroll patients
with metastatic stage III and stage IV melanoma.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 25, 2021 06:13 ET (10:13 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024